Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CytomX Therapeutics (CTMX) Operating Margin (2016 - 2025)

CytomX Therapeutics' Operating Margin history spans 12 years, with the latest figure at 1382.5% for Q4 2025.

  • For Q4 2025, Operating Margin fell 142891.0% year-over-year to 1382.5%; the TTM value through Dec 2025 reached 4.72%, down 2282.0%, while the annual FY2025 figure was 4.72%, 2282.0% down from the prior year.
  • Operating Margin reached 1382.5% in Q4 2025 per CTMX's latest filing, down from 264.43% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 46.41% in Q4 2024 to a low of 1382.5% in Q4 2025.
  • Average Operating Margin over 5 years is 186.35%, with a median of 40.45% recorded in 2022.
  • Peak YoY movement for Operating Margin: surged 33061bps in 2023, then plummeted -142891bps in 2025.
  • A 5-year view of Operating Margin shows it stood at 313.54% in 2021, then surged by 85bps to 47.25% in 2022, then skyrocketed by 95bps to 2.28% in 2023, then surged by 2138bps to 46.41% in 2024, then crashed by -3079bps to 1382.5% in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Operating Margin are 1382.5% (Q4 2025), 264.43% (Q3 2025), and 6.89% (Q2 2025).